SHANGHAI, Sept. 20, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been...
from PR Newswire: https://ift.tt/3kzCCHd
No comments:
Post a Comment